Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
TECH
$50.42
Bio-Techne
$.27
.54%
TECH
Earnings Whisper ®
N/A
1st Quarter September 2025
Consensus: $0.38
Revenue: $296.00 Mil
Wednesday
Nov 5
6:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Wednesday, August 6, 2025
Bio-Techne Releases Fourth Quarter Fiscal 2025 Results
What do you expect when TECH reports earnings?
Beat
Meet
Miss
Where is TECH's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$51.83
$51.21
$50.81
$50.19
Support
$49.79
$49.17
$48.77
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Peers
Biogen
Amgen
Gilead Sciences
Neurocrine Biosciences
Repligen
Qiagen N.V.
BioCryst Pharmaceuticals
Stem
Novavax
Sangamo Therapeutics
Expectations
›
Bio-Techne